Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Berkala Ilmu Kesehatan Kulit dan Kelamin Cermin Dunia Kedokteran
Matthew, Franklind
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Terapi Psoriasis di Era Pandemi COVID-19 Kurniawan, Marsha; Matthew, Franklind
Cermin Dunia Kedokteran Vol 48, No 7 (2021): Infeksi - [Covid - 19]
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (129.621 KB) | DOI: 10.55175/cdk.v48i7.1449

Abstract

Psoriasis merupakan penyakit inflamasi kronis kulit dengan predisposisi genetik dan autoimun yang kuat. Prevalensi psoriasis di seluruh dunia adalah 0,09% sampai 5,1%, bervariasi antar negara. Psoriasis dikarakteristikkan dengan lesi plak eritematosa yang dilapisi skuama tebal putih keabuan, biasanya memiliki predileksi simestris di siku, lutut, trunk, dan scalp. Terapi sebagian besar menggunakan imunomodulator atau imunosupresan untuk psoriasis derajat sedang hingga berat. Sudah terdapat beberapa penelitian efek samping dan rekomendasi dosis obat-obatan di era COVID-19. Penggunaan terapi tersebut dalam era pandemi COVID-19 harus hati-hati dan tetap menjaga imunitas pasien.Psoriasis is a chronic skin inflammatory disease with a strong genetic and autoimmune predisposition. The prevalence of psoriasis worldwide is 0.09% to 5.1%, varies among countries. Psoriasis is characterized by erythematous plaque lesions covered in thick gray-white scales, usually have a symmetrical predilection on the elbows, knees, trunk, and scalp. Immunomodulators or immunosuppressants are commonly used for moderate to severe psoriasis. There have been several studies on side effects and recommendations for the necessary dosage adjustments in the era of the COVID-19 pandemic. Careful use is important to maintain patient's immunity.
Zoliflodacin, A Novel Antimirobial Agent Against neisseria Gonorhoeae: A Systematic Rreview of Quasi-Experimental Studies Matthew, Franklind; Stella, Maureen Miracle; Tandarto, Kevin; Regina, Regina
Berkala Ilmu Kesehatan Kulit dan Kelamin Vol. 36 No. 1 (2024): APRIL
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bikk.V36.1.2024.68-74

Abstract

Background: The gram-negative bacteria Neisseria gonorrhoeae is the source of the STI known as gonorrhea. N. gonorrhoeae can adapt well to humans as a host and become a pathogen with sophisticated mechanisms to avoid the innate immune response as well as suppress the adaptive immune response. Lately, zoliflodacin was shown to have antibacterial activity against N. gonorrhoeae. Purpose: The aim of this study is to evaluate the antibacterial activity of zoliflodacin against N. gonorrhoeae. Methods: We followed the PRISMA 2020 guidelines to systematically search and collect literature in the following databases: ProQuest, EBSCOhost, PubMed, ScienceDirect, Taylor&Francis, SAGE, JSTOR, and Wiley, without time limitation (until October 9th,  2022). Titles and abstracts were reviewed for relevance. The inclusion criteria were original article written in English that investigated the effects of zoliflodacin in patients with gonorrhea. From 177 studies, we retrieved five studies for this study, published between 2015 and 2021. Results: Zoliflodacin was highly active in vitro against N. gonorrhoeae isolates from European countries, China, Thailand, and South Africa, and also showed potent antimicrobial activity against multi-resistant N. gonorrhoeae isolates in South Korea. There were three different kinds of minimum inhibitory concentration (MIC) evaluated, with the following results: modal MIC (0.064-0.25 μg/mL), MIC50 (0.03-0.125 μg/mL), and MIC90 (0.06-0.25 μg/mL). There was no cross-resistance to antimicrobials currently or previously used for gonorrhea treatment. This MIC range could be used for further studies.
Co-Authors Kurniawan, Marsha Regina Regina Stella, Maureen Miracle Tandarto, Kevin